Lexicon Pharmaceuticals, INC. 8-K Filing
Ticker: LXRX · Form: 8-K · Filed: Nov 10, 2025 · CIK: 1062822
| Field | Detail |
|---|---|
| Company | Lexicon Pharmaceuticals, INC. (LXRX) |
| Form Type | 8-K |
| Filed Date | Nov 10, 2025 |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $0, $75,000,000 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Lexicon Pharmaceuticals, INC. (ticker: LXRX) to the SEC on Nov 10, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (ich registered Common stock, par value $0.001 LXRX The Nasdaq Capital Market Che); $0 (, shares of its common stock, par value $0.001, having an aggregate sales price of); $75,000,000 (aving an aggregate sales price of up to $75,000,000 (the "Shares"), filed a prospectus supp).
How long is this filing?
Lexicon Pharmaceuticals, INC.'s 8-K filing is 2 pages with approximately 640 words. Estimated reading time is 3 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 640 words · 3 min read · ~2 pages · Grade level 13.2 · Accepted 2025-11-10 16:31:01
Key Financial Figures
- $0.001 — ich registered Common stock, par value $0.001 LXRX The Nasdaq Capital Market Che
- $0 — , shares of its common stock, par value $0.001, having an aggregate sales price of
- $75,000,000 — aving an aggregate sales price of up to $75,000,000 (the "Shares"), filed a prospectus supp
Filing Documents
- d30705d8k.htm (8-K) — 23KB
- 0001193125-25-274383.txt ( ) — 134KB
- lxrx-20251106.xsd (EX-101.SCH) — 3KB
- lxrx-20251106_lab.xml (EX-101.LAB) — 18KB
- lxrx-20251106_pre.xml (EX-101.PRE) — 11KB
- d30705d8k_htm.xml (XML) — 4KB
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Lexicon Pharmaceuticals, Inc. Date: November 10, 2025 By: /s/ Brian T. Crum Brian T. Crum Senior Vice President and General Counsel